ARHGAP20

Across TCGA pan-cancer cohorts, ARHGAP20 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGAP20 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ARHGAP20 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP20 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, READ, and UCEC are the cancer types where ARHGAP20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.067	0.865	<.001	30	view →
READ	OS	Median	II,III,IV	0.111	0.919	<.001	30	view →
UCEC	DFS	Median	II,III,IV	0.933	0.432	.012	28	view →
BLCA	DFS	Median	All	0.391	0.598	.006	10	view →
BRCA	OS	Median	II,III,IV	0.183	0.567	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGAP20–KIRC (DFS)

Open the KIRC breakdown →